JP2021515576A5 - - Google Patents

Info

Publication number
JP2021515576A5
JP2021515576A5 JP2020548962A JP2020548962A JP2021515576A5 JP 2021515576 A5 JP2021515576 A5 JP 2021515576A5 JP 2020548962 A JP2020548962 A JP 2020548962A JP 2020548962 A JP2020548962 A JP 2020548962A JP 2021515576 A5 JP2021515576 A5 JP 2021515576A5
Authority
JP
Japan
Prior art keywords
cells
item
follistatin
subject
cell
Prior art date
Application number
JP2020548962A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019178613A5 (https=
JP2021515576A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022821 external-priority patent/WO2019178613A1/en
Publication of JP2021515576A publication Critical patent/JP2021515576A/ja
Publication of JPWO2019178613A5 publication Critical patent/JPWO2019178613A5/ja
Publication of JP2021515576A5 publication Critical patent/JP2021515576A5/ja
Priority to JP2023129040A priority Critical patent/JP2023138660A/ja
Priority to JP2025203919A priority patent/JP2026026184A/ja
Pending legal-status Critical Current

Links

JP2020548962A 2018-03-16 2019-03-18 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法 Pending JP2021515576A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023129040A JP2023138660A (ja) 2018-03-16 2023-08-08 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法
JP2025203919A JP2026026184A (ja) 2018-03-16 2025-11-26 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862644362P 2018-03-16 2018-03-16
US201862644356P 2018-03-16 2018-03-16
US62/644,356 2018-03-16
US62/644,362 2018-03-16
PCT/US2019/022821 WO2019178613A1 (en) 2018-03-16 2019-03-18 B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023129040A Division JP2023138660A (ja) 2018-03-16 2023-08-08 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法

Publications (3)

Publication Number Publication Date
JP2021515576A JP2021515576A (ja) 2021-06-24
JPWO2019178613A5 JPWO2019178613A5 (https=) 2022-03-29
JP2021515576A5 true JP2021515576A5 (https=) 2022-03-29

Family

ID=65995892

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020548962A Pending JP2021515576A (ja) 2018-03-16 2019-03-18 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法
JP2023129040A Withdrawn JP2023138660A (ja) 2018-03-16 2023-08-08 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法
JP2025203919A Pending JP2026026184A (ja) 2018-03-16 2025-11-26 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023129040A Withdrawn JP2023138660A (ja) 2018-03-16 2023-08-08 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法
JP2025203919A Pending JP2026026184A (ja) 2018-03-16 2025-11-26 フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法

Country Status (7)

Country Link
US (1) US20210047619A1 (https=)
EP (1) EP3765601A1 (https=)
JP (3) JP2021515576A (https=)
CN (1) CN111936617A (https=)
AU (2) AU2019233929B2 (https=)
CA (1) CA3093716A1 (https=)
WO (1) WO2019178613A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2971039T (pt) 2013-03-14 2020-05-06 Immusoft Corp Métodos para diferenciação e transdução in vitro de células b de memória com vetores virais pseudotipados vsv-g
NZ758331A (en) * 2017-04-27 2025-12-19 Immusoft Corp B cells for in vivo delivery of therapeutic agents and dosages thereof
EP3870604B1 (en) 2018-10-26 2022-11-23 F. Hoffmann-La Roche AG Multispecific antibody screening method using recombinase mediated cassette exchange
CN113677354A (zh) * 2019-01-23 2021-11-19 综合医院公司 B细胞免疫疗法
CA3094859A1 (en) * 2020-10-01 2022-04-01 Entos Pharmaceuticals Inc. Proteolipid vesicles formulated with fusion associated small transmembrane proteins
KR20260048589A (ko) * 2023-08-29 2026-04-10 후지필름 가부시키가이샤 바이러스의 제조 방법 및 세포로의 핵산 도입 방법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US5124259A (en) 1989-08-23 1992-06-23 Mitsui Toatsu Chemicals, Inc. Method for electroporation
US5297983A (en) 1991-07-15 1994-03-29 Albert Handtmann Maschinenfabrik Gmbh & Co., Kg Process and device for separating and placing a gut caterpillar on a filling tube
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
DE69420024T2 (de) 1993-08-10 2000-02-24 W.L. Gore & Associates, Inc. Zelleinkapselungsvorrichtung
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
WO1996039993A1 (en) 1995-06-07 1996-12-19 Gore Hybrid Technologies, Inc. An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
AU6854696A (en) 1995-09-22 1997-04-09 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
KR20030076685A (ko) 2001-02-19 2003-09-26 포라 가세이 고교 가부시키가이샤 일렉트로포레이션용 조성물
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
CN1929734A (zh) * 2002-02-21 2007-03-14 惠氏公司 含卵泡抑素区的蛋白质
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
JP4688483B2 (ja) * 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
CN109045307A (zh) * 2004-06-01 2018-12-21 健泰科生物技术公司 抗体-药物偶联物和方法
KR20070060115A (ko) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
CA2538208A1 (en) * 2005-05-04 2006-11-04 Universite Laval Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
AU2006272634B2 (en) 2005-07-26 2013-01-24 Sangamo Therapeutics, Inc. Targeted integration and expression of exogenous nucleic acid sequences
CA2891996A1 (en) 2005-10-18 2007-04-26 Duke University Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity
US7799555B2 (en) 2006-02-10 2010-09-21 Bio-Rad Laboratories, Inc. Apparatus for high-throughput electroporation
AU2008317354B2 (en) 2007-10-25 2014-04-10 Ospedale San Raffaele S.R.L. Methods and compositions for targeted integration
US8551780B2 (en) 2008-02-01 2013-10-08 H. Lee Moffitt Cancer Center & Research Institute, Inc. Electroporation buffer composition and method of use
EP2281050B1 (en) 2008-04-14 2014-04-02 Sangamo BioSciences, Inc. Linear donor constructs for targeted integration
SG191561A1 (en) 2008-08-22 2013-07-31 Sangamo Biosciences Inc Methods and compositions for targeted single-stranded cleavage and targeted integration
JP5726744B2 (ja) 2008-11-21 2015-06-03 カリフォルニア インスティチュート オブ テクノロジー 生体外におけるヒトｂリンパ球産生培養システム
CA2786664C (en) 2010-01-08 2020-03-10 Immusoft Corporation Vectors and methods for transducing b cells
EP2534163B1 (en) 2010-02-09 2015-11-04 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
WO2011114678A1 (ja) 2010-03-15 2011-09-22 国立大学法人山口大学 哺乳動物細胞への遺伝子導入効率の向上剤
JP6208580B2 (ja) 2010-05-17 2017-10-04 サンガモ セラピューティクス， インコーポレイテッド 新規のｄｎａ結合タンパク質及びその使用
CA2863964C (en) * 2012-02-07 2021-10-26 Global Bio Therapeutics Usa, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
EA201590719A1 (ru) * 2013-01-25 2015-12-30 Шир Хьюман Дженетик Терапис, Инк. Фоллистатин в лечении мышечной дистрофии дюшенна
PT2971039T (pt) 2013-03-14 2020-05-06 Immusoft Corp Métodos para diferenciação e transdução in vitro de células b de memória com vetores virais pseudotipados vsv-g
CA2945320A1 (en) * 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Drug regulated transgene expression
US10023621B2 (en) * 2014-06-04 2018-07-17 Acceleron Pharma Inc. Follistatin-related fusion proteins
US10010498B2 (en) * 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
WO2016057975A2 (en) * 2014-10-10 2016-04-14 Research Institute At Nationwide Children's Hospital Guided injections for aav gene transfer to muscle
DK3234107T3 (da) * 2014-12-19 2022-10-17 Immusoft Corp B-celler til in vivo-levering af terapeutiske midler
US10350245B2 (en) * 2015-01-21 2019-07-16 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
AU2016243052C1 (en) * 2015-04-03 2022-11-24 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of B-cells
AU2016297014B2 (en) * 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells

Similar Documents

Publication Publication Date Title
JP2021515576A5 (https=)
Ghasemi et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy
Fung et al. Activation of group 2 innate lymphoid cells alleviates aging-associated cognitive decline
TWI908706B (zh) ＣＡＲＴｙｒｉｎ組成物和使用方法
JP2023138660A5 (https=)
US11213548B2 (en) Modulatable switch for selection of donor modified cells
JP7235391B2 (ja) 人工的に操作された免疫細胞
CA2889299C (en) Novel method for treating spinal cord injury using hmgb1 fragment
ES2665328T3 (es) Células que expresan STRO-1bright para tratar la enfermedad de injerto contra huésped
CN101374945A (zh) 得自人脂肪的细胞的免疫表型和免疫原性
KR20230018378A (ko) 골수 세포 및 미세아교세포에서 치료 단백질을 특이적으로 발현하는 바이러스 벡터
JPWO2019178613A5 (https=)
CN111499766B (zh) 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用
CN117338914A (zh) 一种同种异体树突细胞肿瘤疫苗及其制备方法和应用
EP1355661A2 (de) Tumorvakzine
Korchak et al. Endothelial nitric oxide synthase-engineered mesenchymal stromal cells induce anti-inflammation in experimental immune models
JP2003531816A (ja) 遺伝子導入産物に機能的寛容を誘導する方法
EP4006145A1 (en) Method for preparation of immortalized stem cell line and use thereof
RU2020133851A (ru) B-клетки, генетически модифицированные для секреции фоллистатина, и способы их применения для лечения связанных с фоллистатином заболеваний, состояний, нарушений и для увеличения роста и силы мышц
CN101083910B (zh) 用于预防和治疗移植中的免疫应答的肝脏基质细胞
Candotti Gene therapy for immunodeficiency
CN120098141A (zh) 一种通用型抗肿瘤的SynNotch合成受体组合及其应用
WO2018037105A1 (en) Psammaplin a for modulating ido expression
CN115975050A (zh) 嵌合的人源t细胞受体、核酸、载体、细胞和药物组合物
CN119799717A (zh) 核酸形式il-9联合免疫检查点药物的制剂组合与应用